Clinical Trials Browser

Phase 2 × Has results × etirinotecan pegol × Clear all

NCT02312622 2023-12-12

Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer

Phase 2 Completed

27 enrolled 19 charts

BreastCNSThoracic

Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

NCT00598975 2021-07-12

NKTR-102 in Combination With Cetuximab in Patients With Refractory Solid Tumors (Phase 2a) and Metastatic or Locally Advanced Colorectal Cancer (Phase 2b)

Phase 2 Completed

18 enrolled 13 charts

Gastrointestinal

Neoplasms, Colorectal Neoplasms

NCT00856375 2021-07-12

NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer

Phase 2 Completed

83 enrolled 13 charts

Gastrointestinal

Colorectal Neoplasms

NCT01457118 2021-07-12

An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies

Phase 2 Completed

27 enrolled 18 charts

Other solid neoplasm

Malignant Solid Tumor

NCT01773109 2020-04-03

Etirinotecan Pegol (NKTR-102) in NSCLC

Phase 2 Completed

40 enrolled 9 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT01876446 2020-03-17

Pegylated Irinotecan NKTR 102 in Treating Patients With Relapsed Small Cell Lung Cancer

Phase 2 Completed

38 enrolled 16 charts

Small Cell Lung Carcinoma

NCT00802945 2018-07-09

Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Breast Cancer

Phase 2 Completed

70 enrolled 15 charts

Breast Neoplasms, Neoplasms

NCT01663012 2016-02-24

Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma

Phase 2 Completed

20 enrolled 10 charts

Astrocytoma, Glioblastoma, Oligodendroglioma